To conclude, regarding PD-L1 expression in TETs studied by immunohistochemistry, we should note that, to our knowledge, our research includes one of the largest published cohorts (91 patients), assessing PD-L1 expression in tumor cells and infiltrating immune cells with two different PD-L1 antibody clones. This evidence concerns the gene CD274 and neoplasm.